公开(公告)号：EP0637963A1

公开(公告)日：1995-02-15

申请号：EP93910570.0

申请日：1993-04-06

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY

发明人： THOMPSON, Craig, B. c/o Howard Hughes Med. Inst. ,  JUNE, Carl, H.

IPC分类号： C12N15 ,  A61K35 ,  A61K38 ,  A61K39 ,  A61P31 ,  A61P37 ,  C07K14 ,  C07K16 ,  C12N5 ,  C12P21

CPC分类号： C12N5/0636 ,  A61K31/395 ,  A61K35/17 ,  A61K38/2013 ,  A61K38/45 ,  A61K38/465 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K14/70521 ,  C07K16/00 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2833 ,  C07K16/2866 ,  C07K16/289 ,  C07K16/2896 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/30 ,  C12N2501/51 ,  C12N2501/515 ,  A61K2300/00

摘要： Use of an anti-CD28 antibody or a F(ab')2 fragment thereof in the manufacture of a medicament for administration to a population of CD3-activated CD28 T-cells of a patient to promote the production of a cyclosporine resistant lymphokine selected from IL-2, TNF, IFN-gamma and GM-CSF.

公开(公告)号：EP0445228A1

公开(公告)日：1991-09-11

申请号：EP90901248.0

申请日：1989-11-22

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  Bristol-Myers Squibb Company

发明人： THOMPSON, Craig, B. ,  JUNE, Carl, H. ,  LEDBETTER, Jeffrey, A. ,  LINDSTEN, Tullia

IPC分类号： A61K39 ,  A61K35 ,  A61K38 ,  A61K45 ,  A61P37 ,  C07K14 ,  C07K16 ,  C12N5

CPC分类号： A61K39/02 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K14/70521 ,  C07K16/00 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2833 ,  C07K16/2866 ,  C07K16/289 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N5/0636 ,  C12N2501/51 ,  C12N2501/515

摘要： Un procédé d'immunothérapie stimule la molécule de surface CD28 de cellules T afin d'augmenter la prolifération de cellules T et d'élever les niveaux globaux de lymphokine et/ou d'accroître la production cellulaire de lymphokines TH1 humaines. Le procédé est sélectif pour le déclenchement de réponses immunes induites par des cellules T activées, et stimule la fonction immune même en présence d'immunosuppresseurs.

公开(公告)号：EP3402877A1

公开(公告)日：2018-11-21

申请号：EP16834056.0

申请日：2016-12-19

申请人： Gdanski Uniwersytet Medyczny

发明人： MAREK-TRZONKOWSKA, Natalia ,  TRZONKOWSKl, Piotr ,  MYSLIWIEC, Malgorzata

IPC分类号： C12N5/0783

CPC分类号： C12N5/0637 ,  C12N2500/00 ,  C12N2501/2302 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/998 ,  C12N2523/00

摘要： The invention relates to a new method for in vitro expansion of CD4+CD25HighCD127−/LOWfoxP3+Tregs, wherein the process of Treg expansion takes place permanently or temporarily at a temperature below 37° C., optimally at a temperature of 33° C., the isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum, and magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 (cell:bead) ratio and interleukin-2 are added to the culture.

公开(公告)号：EP3214091B1

公开(公告)日：2018-10-03

申请号：EP17153799.6

申请日：2011-12-09

申请人： The Trustees of The University of Pennsylvania

发明人： JUNE, Carl H. ,  LEVINE, Bruce L. ,  PORTER, David L. ,  KALOS, Michael D. ,  MILONE, Michael C.

IPC分类号： C07H21/04 ,  A61K39/00

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/5256 ,  A61K2039/585 ,  C07K14/075 ,  C07K14/525 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/80 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/74 ,  C12N7/00 ,  C12N15/85 ,  C12N15/861 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12N2740/15071 ,  A61K2300/00

摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

公开(公告)号：EP3375868A1

公开(公告)日：2018-09-19

申请号：EP18150910.0

申请日：2008-11-07

申请人： Dana Farber Cancer Institute, Inc. ,  Beth Israel Deaconess Medical Center

发明人： AVIGAN, David ,  KUFE, Donald

IPC分类号： C12N5/12 ,  C12N5/16 ,  A61K39/00 ,  G01N33/00

CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55538 ,  C12N5/0636 ,  C12N5/16 ,  C12N2501/056 ,  C12N2501/23 ,  C12N2501/51 ,  C12N2501/515

摘要： The invention is concerned with fusions of dendritic cells and with tumor or cancer cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy as well as methods of stimulating anti-tumor immunity using fused cells and anti-CD3/CD28 antibodies.

公开(公告)号：EP3341474A1

公开(公告)日：2018-07-04

申请号：EP16840406.9

申请日：2016-08-26

申请人： CTM@CRC Ltd.

发明人： BARRY, Simon ,  DELALAT, Bahman ,  GUNDSAMBUU, Batjargal ,  HARDING, Frances, Jane ,  HUTMACHER, Dietmar ,  PARDO, Maria, Elena, Juan ,  VOELCKER, Nicolas, Hans ,  WUNNER, Felix

IPC分类号： C12N5/0783 ,  C12N5/02 ,  A61F2/02

CPC分类号： A61L27/56 ,  A61L27/54 ,  A61L2300/252 ,  A61L2300/256 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/74 ,  C07K2317/75 ,  C12N5/0636 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2533/00

摘要： The present disclosure relates to products and methods for activating and/or expanding T cells. Certain embodiments of the present disclosure provide a porous scaffold comprising one or more conjugated T cell stimulatory molecules.

公开(公告)号：EP3294872A1

公开(公告)日：2018-03-21

申请号：EP16736931

申请日：2016-05-12

申请人： TERUMO BCT INC

发明人： NGUYEN KIM THIEN DUY ,  STARTZ THOMAS PATRICK ,  HOWARD ALEXANDER L

IPC分类号： C12N5/0783 ,  C12M3/06

CPC分类号： C12N5/0636 ,  C12M21/08 ,  C12M23/06 ,  C12M23/44 ,  C12M25/10 ,  C12M27/00 ,  C12M41/48 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2527/00

摘要： Embodiments are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In embodiments, the cells may be exposed to an activator for activating expansion of the cells. The cells may in embodiments include T cells, and the activator may be in different forms, including, for example, antigen presenting cells or beads functionalized with antibodies.

公开(公告)号：EP3154555A4

公开(公告)日：2018-02-28

申请号：EP15807341

申请日：2015-06-10

申请人： UNIV MONASH

发明人： TIGANIS TONY ,  WIEDE FLORIAN

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/113

CPC分类号： C12N5/0638 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/73 ,  C12Y301/03048

摘要： The present invention generally relates to methods of preparing leukocytes, particularly T cells, ex vivo for use in immunotherapy, particularly cancer immunotherapy. More specifically, the invention relates to methods for the preparation of leukocytes exhibiting cytotoxic properties for use in adoptive cell transfer. The invention also relates to cells and compositions including them for cancer immunotherapy. The invention also relates to methods of immunotherapy, particularly cancer immunotherapy. The present invention relates to a method for producing a leukocyte that has an enhanced capacity for killing a target cell, the method including contacting the leukocyte with a PTPN2 inhibitor in conditions for enabling the inhibitor to inactivate PTPN2 in the leukocyte, thereby producing a leukocyte that has an enhanced capacity for killing a target cell. Preferably, the leukocyte is contacted with the PTPN2 inhibitor in the absence of a T helper cell.

公开(公告)号：EP2856876B1

公开(公告)日：2018-01-31

申请号：EP14185125.3

申请日：2008-03-31

申请人： Memorial Sloan-Kettering Cancer Center

发明人： Sadelain, Michel ,  Stephan, Matthias

IPC分类号： A61K39/00 ,  A61K45/06 ,  A61K35/17 ,  C12N5/0783 ,  A61K38/20 ,  A61K38/21 ,  C12N7/00 ,  A61K35/12 ,  C12N15/85

CPC分类号： A61K35/17 ,  A61K38/2013 ,  A61K38/217 ,  A61K39/0011 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/85 ,  C12N2501/25 ,  C12N2501/51 ,  C12N2501/599 ,  C12N2510/00 ,  C12N2799/04

摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

公开(公告)号：EP3271455A1

公开(公告)日：2018-01-24

申请号：EP16769492.6

申请日：2016-03-21

申请人： Children's National Medical Center

发明人： BOLLARD, Catherine ,  CRUZ, Conrad ,  HANLEY, Patrick

IPC分类号： C12N5/0783 ,  C12N5/0784 ,  C07K14/075 ,  C07K14/54 ,  C07K14/535 ,  A61K39/295

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K39/00 ,  A61K39/295 ,  A61K2039/5158 ,  C07K14/075 ,  C07K14/535 ,  C07K14/5406 ,  C07K14/55 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/51 ,  C12N2501/59 ,  C12N2502/1121 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/467

摘要： Safe, rapid and efficient methods for producing virus-specific or other antigen-specific T-cells from cord blood and other samples containing naive immune cells.